Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Summary
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Official title: An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2025-09-01
Completion Date
2030-09-01
Last Updated
2025-08-26
Healthy Volunteers
No
Conditions
Interventions
23-valent pneumococcal vaccine
Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine